Picture of Zydus Lifesciences logo

ZYDUSLIFE — Zydus Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Brief: Zydus Lifesciences Says US FDA Grants Priority Review To Zydus Therapeutics' NDA For Saroglitazar To Treat Pbc

BRIEF-Zydus Lifesciences Says US FDA Grants Priority Review To Zydus Therapeutics' NDA For Saroglitazar To Treat Pbc

- Zydus Lifesciences Ltd ZYDU.NS:

  • US FDA GRANTS PRIORITY REVIEW TO ZYDUS THERAPEUTICS' NDA FOR SAROGLITAZAR TO TREAT PBC

Source text: ID:nNSE4JhhBV

Further company coverage: ZYDU.NS


((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zydus Lifesciences

See all news